Recent News

• 11.05.2026 - Iovance Biotherapeutics Reports Record Third Quarter 2026 Revenue of ~$122M, Business Achievements, and Corporate Updates
• 10.29.2026 - Iovance Reports Updated IOV-LUN-202 Results and Adds Precision TIL Strategy for Second-Line Metastatic Non-Small-Cell Lung Cancer (mNSCLC)
• 10.28.2026 - Iovance Biotherapeutics to Host Webcast on Positive Data for TIL Therapy in Metastatic Non-Small Cell Lung Cancer (mNSCLC) and Broader Precision Medicine Strategy
• 10.27.2026 - Iovance Biotherapeutics to Report Third Quarter 2026 Financial Results and Corporate Updates on Thursday, November 5, 2026
• 10.26.2026 - Iovance Announces Data Showing Durable Responses with Lifileucel TIL Cell Therapy in Advanced Soft Tissue Sarcomas at ESMO 2026
• 10.23.2026 - Iovance Presents New Data at ESMO 2026 Demonstrating Deep, Durable Responses with Lifileucel TIL Cell Therapy Plus Pembrolizumab in Frontline Advanced Melanoma
• 10.19.2026 - Iovance Highlights TIL Cell Therapy Platform Across Solid Tumors at the European Society for Medical Oncology (ESMO) Congress 2026
• 10.01.2026 - Iovance Biotherapeutics Appoints Noah Berkowitz, M.D., Ph.D., as Chief Medical Officer
• 09.29.2026 - Iovance Biotherapeutics Raises Full Year 2026 Revenue Guidance to $410 to $420 Million
• 09.18.2026 - Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Recent Filings

• 10.29.2026 - 8-K Current report
• 10.29.2026 - EX-99.1 EX-99.1
• 10.05.2026 - 8-K Current report
• 10.05.2026 - EX-99.1 EX-99.1
• 10.02.2026 - 4 Statement of changes in beneficial ownership of securities
• 10.02.2026 - 3 Initial statement of beneficial ownership of securities
• 09.29.2026 - 8-K Current report
• 09.29.2026 - EX-99.1 EX-99.1
• 09.10.2026 - 4 Statement of changes in beneficial ownership of securities
• 09.10.2026 - 4 Statement of changes in beneficial ownership of securities